Prospective study on the clinical efficacy of Darolutamide in non-metastatic castration-resistant prostate cancer
Latest Information Update: 29 Jun 2021
At a glance
- Drugs Darolutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 27 Jun 2021 Status changed from not yet recruiting to recruiting.
- 06 Aug 2020 New trial record